Newsfiscal.ai
Scribe Therapeutics to Present Updated Data at AHA Scientific Sessions 2026
· Published
Article summary
Scribe Therapeutics announced it will present new preclinical data for its lead epigenetic silencing therapy, STX-1150, and its gene editing program, STX-1200, at the American Heart Association's Scientific Sessions.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…